Back to Journals » Breast Cancer: Targets and Therapy » Volume 7

Cardiac risk in the treatment of breast cancer: assessment and management

Authors Valachis A, Nilsson C

Received 14 October 2014

Accepted for publication 20 November 2014

Published 16 January 2015 Volume 2015:7 Pages 21—35


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Pranela Rameshwar

Antonis Valachis,1 Cecilia Nilsson2

1Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden; 2Center for Clinical Research, Västmanlands County Hospital, Västerås, Sweden

Abstract: As the number of long-term breast cancer survivors has increased, the side effects of adjuvant cancer therapy, such as cardiac toxicity, remain clinically important. Although the cardiac toxicity due to anthracyclines, radiotherapy, or trastuzumab is well-documented, several issues need to be clarified and are the subjects of extensive ongoing clinical research. This review summarizes the incidence of cardiac toxicity due to breast cancer adjuvant therapy and highlights the current trends in early detection and management of cardiac toxicities.

Keywords: adjuvant, anthracyclines, cardiac toxicity, radiotherapy, trastuzumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]